XML 33 R22.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 8, 2026, the Company entered into a Research Collaboration and License Agreement, or the 2026 Roche Agreement, with Roche to collaborate on the discovery, development and commercialization of DACs. The Company and Roche have a pre-existing material relationship arising from the 2018 Roche Agreement. Pursuant to the terms of the 2026 Roche Agreement, the Company granted Roche a worldwide, exclusive license under certain of the Company's intellectual property rights to develop, manufacture and commercialize DACs directed to two initial undisclosed oncology targets. After the collaboration term and a decision by Roche to proceed with development, Roche is solely responsible for all development, regulatory approval, manufacturing and commercialization costs. Under the terms of the 2026 Roche Agreement, Roche has made an upfront cash payment of $20.0 million. In addition, across the collaboration, C4T is eligible to receive over $1.0 billion in aggregate development, regulatory and commercial milestone payments, plus tiered royalties on net sales.